相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations
Chiea Chuen Khor et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)
The Impact of the CYP2D6 Enhancer Single Nucleotide Polymorphism on CYP2D6 Activity
Jean C. Dinh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Quantification ofIn VivoMetabolic Activity ofCYP2D6Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine
Trine Frederiksen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Tri-Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41
Ulrich M. Zanger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Relationships betweenCYP1A2,CYP2C9,CYP2C19,CYP2D6andCYP3A4metabolic phenotypes and genotypes in a Nicaraguan Mestizo population
Fernando de Andres et al.
PHARMACOGENOMICS JOURNAL (2021)
Allele-specific alternative splicing and its functional genetic variants in human tissues
Kofi Amoah et al.
GENOME RESEARCH (2021)
Cytochrome P450 3A4 (CYP3A4) protein quantification using capillary western blot technology and total protein normalization
Joseph M. Collins et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2021)
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data
Maaike van der Lee et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
PharmVar GeneFocus: CYP2D6
Charity Nofziger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Distribution and linkage disequilibrium of the enhancer SNP rs5758550 among Latin American populations: influence of continental ancestry
Anna Beatriz Ribeiro Elias et al.
PHARMACOGENETICS AND GENOMICS (2020)
The GTEx Consortium atlas of genetic regulatory effects across human tissues
Francois Aguet et al.
SCIENCE (2020)
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores
Cameron D. Thomas et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy
Jacob T. Brown et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels
Balmiki Ray et al.
PHARMACOGENETICS AND GENOMICS (2019)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Matthew P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue
Miaoran Ning et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
The effect of rs5758550 on CYP2D6☆2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen
Anabel B. Sanchez-Spitman et al.
PHARMACOGENOMICS (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron
G. C. Bell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update
J. K. Hicks et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants
Mitchell J. Machiela et al.
BIOINFORMATICS (2015)
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
Daniel L. Hertz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
J. K. Hicks et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Functional characterization of CYP2D6 enhancer polymorphisms
Danxin Wang et al.
HUMAN MOLECULAR GENETICS (2015)
A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication
Taimour Langaee et al.
PLOS ONE (2015)
Mechanism of alternative splicing and its regulation
Yan Wang et al.
BIOMEDICAL REPORTS (2015)
Role of Protein-Protein Interactions in Cytochrome P450-Mediated Drug Metabolism and Toxicity
Sylvie E. Kandel et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
K. R. Crews et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Functional Characterization of Wild-type and 49 CYP2D6 Allelic Variants for N-Desmethyltamoxifen 4-Hydroxylation Activity
Yuka Muroi et al.
DRUG METABOLISM AND PHARMACOKINETICS (2014)
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity
Danxin Wang et al.
HUMAN MOLECULAR GENETICS (2014)
Pharmacogenetics: Implications of race and ethnicity on defining genetic profiles for personalized medicine
Victor E. Ortega et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants
Lazara Karelia Montane Jaime et al.
PHARMACOGENOMICS (2013)
Effect of homomeric P450-P450 complexes on P450 function
James R. Reed et al.
BIOCHEMICAL JOURNAL (2012)
An integrated map of genetic variation from 1,092 human genomes
David M. Altshuler et al.
NATURE (2012)
CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
A. LLerena et al.
PHARMACOGENOMICS JOURNAL (2012)
Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
K. Abduljalil et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting
Michelle Cook Sangar et al.
MOLECULAR GENETICS AND METABOLISM (2010)
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The 2988G>A polymorphism affects splicing of a CYP2D6 minigene
Thomas Rau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A:: evidence for modulation of splicing events
Claudia Toscano et al.
PHARMACOGENETICS AND GENOMICS (2006)
Crystal structure of human cytochrome P450 2D6
P Rowland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
CYP2D6 genotyping by a multiplex primer extension reaction
J Sistonen et al.
CLINICAL CHEMISTRY (2005)
Tramadol as a new probe for cytochrome P450 2D6 phenotyping: A population study
RS Pedersen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
M Ingelman-Sundberg
PHARMACOGENOMICS JOURNAL (2005)
Stable expression of human cytochrome P450 2D6*10 in HepG2 cells
J Zhuge et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6
UM Zanger et al.
PHARMACOGENETICS (2001)
分享论文
